WASHINGTON, DC – March 27, 2014 –A new angiographic analysis of the CHAMPION PHOENIX trial examined the incidence and impact of stent thrombosis (ST) in patients undergoing percutaneous coronary intervention (PCI). Results of the study were released today and will be presented March 30 at the American College of Cardiology 63rd Annual Scientific Session.

RIDGEFIELD, Conn., March 28, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced results from a new survey of cardiologists to understand their perceptions about anticoagulation, stroke risk reduction and goals for non-valvular atrial fibrillation (NVAF) therapy when prescribing warfarin or a novel oral anticoagulant. The online survey, conducted by Harris Poll on behalf of BIPI, included 300 licensed U.S. cardiologists who treat at least five NVAF patients per month.

WASHINGTON, D.C., March 28, 2014 – With the unmatched flexibility to measure radiation peak skin dose in real time, Toshiba America Medical Systems, Inc.’s Dose Tracking System is the latest advancement in optimizing dose management for its InfinixTM-i cardiovascular X-ray systems during adult and pediatric interventional procedures.

BURLINGTON, Mass. – March 26, 2014 – Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery disease, today announced that its TVC Imaging System™, a first-in-class dual-modality intravascular imaging system, will be featured in eight scientific posters during the American College of Cardiology’s (ACC) 63rd Annual Scientific Session. The meeting will be held March 29th-31st at the Walter E. Washington Convention Center in Washington, DC.

March 27, 2014—Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of Cardiology's (ACC) 63rd Annual Scientific Session in Washington, DC. These sub-analyses specifically investigated the effects of the dipeptidyl peptidase-4 inhibitor (DPP-4i) alogliptin on rates of CV mortality and hospitalization for heart failure (HF).

PRINCETON, N.J., & NEW YORK (March 27, 2014) -- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial that assessed the effect of blood pressure control on outcomes as well as the treatment effect of Eliquis (apixaban) compared to warfarin according to blood pressure control.1 The results showed that poor blood pressure control was associated with a substantially higher risk of stroke or systemic embolism, independent of Eliquis or warfarin treatment. However, this subanalysis found consistent results for Eliquis versus warfarin in reducing the risk of stroke, regardless of blood pressure control. These data will be presented Saturday, March 29, at the American College of Cardiology’s (ACC) 63rd Annual Scientific Session in Washington, D.C.

Waltham, MA – March 26, 2014 (Booth # 1343) – Corindus Vascular Robotics, the leader in precision vascular robotics, will showcase its FDA-cleared CorPath System at the upcoming American College of Cardiology (ACC) annual meeting, March 29 – 31 in Washington, D.C. The CorPath is the first medical device to bring robotic precision and accuracy to coronary angioplasty to help optimize clinical outcomes. Corindus representatives will be onsite to conduct demos of the CorPath System and answer questions about the significant advantages in procedure precision and improvements in clinical outcomes made possible by robotics in the cath lab.

ACE inhibitors (ACEIs) may warrant consideration as a first-line therapy to prevent death and cardiovascular events in patients with diabetes mellitus, according to a meta-analysis published online March 31 in JAMA Internal Medicine. The analysis found lower rates of mortality and cardiovascular events with ACEIs, but no similar effects with ARBs.